metformin has been researched along with ADPKD in 18 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways." | 9.27 | A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018) |
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 7.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "We found that 50% or more of the maximal metformin dose was safe and well tolerated over 12 months in patients with ADPKD." | 5.51 | Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. ( Brosnahan, GM; Chonchol, MB; George, D; Gitomer, B; Klawitter, J; Nowak, KL; Struemph, T; Wang, W; You, Z, 2022) |
| "Metformin inhibits cyclic AMP generation and activates AMP-activated protein kinase (AMPK), which inhibits the cystic fibrosis transmembrane conductance regulator and Mammalian Target of Rapamycin pathways." | 5.27 | A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. ( Abebe, KZ; Bae, KT; Hallows, KR; Miskulin, DC; Perrone, RD; Seliger, SL; Watnick, T, 2018) |
| "This study showed that the combination of metformin and 2DG blocked the formation of renal cysts and improved the renal function in ADPKD miniature pigs." | 3.91 | The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. ( Bai, XY; Cai, G; Chen, X; Li, Q; Li, Z; Lian, X; Lin, S; Song, K; Wu, X; Zhang, Y, 2019) |
| "We retrospectively examined the records of our ADPKD patients, selecting 7 diabetic ADPKD patients under metformin treatment and 7 matched non-diabetic ADPKD controls, to test the effect of metformin on renal progression during a 3 year follow-up." | 3.88 | Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? ( Bruzzese, D; Pisani, A; Riccio, E; Sabbatini, M, 2018) |
| "Metformin was administrated through daily intraperitoneal injection from postnatal day 35 for 4 weeks." | 3.11 | Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice. ( Chang, MY; Chou, LF; Hsu, SH; Hung, CC; Ong, ACM; Tian, YC; Tsai, CY; Yang, CW; Yang, HY, 2022) |
| "Since ADPKD is a complex disease with a high degree of interindividual heterogeneity, and the mechanisms involved in cyst growth also have important functions in various physiological processes, it may prove difficult to develop drugs that target cyst growth without causing major adverse events." | 2.82 | Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease. ( Bais, T; Gansevoort, RT; Meijer, E, 2022) |
| "The current aim of ADPKD therapy is the inhibition of cyst development and retardation of chronic kidney disease progression." | 2.82 | Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease. ( Andreucci, M; Bolignano, D; Casarella, A; Coppolino, G; De Sarro, G; Deodato, F; Nicotera, R; Presta, P; Russo, E; Urso, A; Zicarelli, MT, 2022) |
| "Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves over-proliferation of cyst-lining epithelial cells and excessive cystic fluid secretion." | 1.72 | PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity. ( Fang, Q; Fu, K; Guo, D; Liu, H; Ren, Y; Su, L; Wang, J; Wang, R; Yin, L; Yuan, H; Zhang, H, 2022) |
| "Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) involves both fluid secretion and abnormal proliferation of cyst-lining epithelial cells." | 1.37 | Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. ( Caplan, MJ; Hallows, KR; Karihaloo, A; King, JD; Li, H; Nishio, S; Seo-Mayer, P; Somlo, S; Takiar, V; Zhang, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, MY | 2 |
| Tsai, CY | 1 |
| Chou, LF | 1 |
| Hsu, SH | 1 |
| Yang, HY | 1 |
| Hung, CC | 2 |
| Tian, YC | 2 |
| Ong, ACM | 2 |
| Yang, CW | 2 |
| Su, L | 1 |
| Yuan, H | 1 |
| Zhang, H | 1 |
| Wang, R | 1 |
| Fu, K | 1 |
| Yin, L | 1 |
| Ren, Y | 1 |
| Liu, H | 1 |
| Fang, Q | 1 |
| Wang, J | 1 |
| Guo, D | 1 |
| Bais, T | 1 |
| Gansevoort, RT | 2 |
| Meijer, E | 1 |
| Leonhard, WN | 1 |
| Song, X | 1 |
| Kanhai, AA | 1 |
| Iliuta, IA | 1 |
| Bozovic, A | 1 |
| Steinberg, GR | 1 |
| Peters, DJM | 1 |
| Pei, Y | 1 |
| Mahendran, R | 1 |
| Lim, SK | 1 |
| Ong, KC | 1 |
| Chua, KH | 1 |
| Chai, HC | 1 |
| Casarella, A | 1 |
| Nicotera, R | 1 |
| Zicarelli, MT | 1 |
| Urso, A | 1 |
| Presta, P | 1 |
| Deodato, F | 1 |
| Bolignano, D | 1 |
| De Sarro, G | 1 |
| Andreucci, M | 1 |
| Russo, E | 1 |
| Coppolino, G | 1 |
| Brosnahan, GM | 1 |
| Wang, W | 1 |
| Gitomer, B | 1 |
| Struemph, T | 1 |
| George, D | 1 |
| You, Z | 1 |
| Nowak, KL | 1 |
| Klawitter, J | 1 |
| Chonchol, MB | 1 |
| Ma, TL | 1 |
| Chen, YC | 1 |
| Cheng, YC | 1 |
| Seliger, SL | 1 |
| Abebe, KZ | 1 |
| Hallows, KR | 2 |
| Miskulin, DC | 1 |
| Perrone, RD | 1 |
| Watnick, T | 1 |
| Bae, KT | 1 |
| Pisani, A | 2 |
| Riccio, E | 2 |
| Bruzzese, D | 1 |
| Sabbatini, M | 1 |
| Lian, X | 1 |
| Wu, X | 1 |
| Li, Z | 1 |
| Zhang, Y | 1 |
| Song, K | 1 |
| Cai, G | 1 |
| Li, Q | 1 |
| Lin, S | 1 |
| Chen, X | 1 |
| Bai, XY | 1 |
| Capuano, I | 1 |
| Caccavallo, S | 1 |
| De Simone, I | 1 |
| Mekahli, D | 1 |
| Decuypere, JP | 1 |
| Sammels, E | 1 |
| Welkenhuyzen, K | 1 |
| Schoeber, J | 1 |
| Audrezet, MP | 1 |
| Corvelyn, A | 1 |
| Dechênes, G | 1 |
| Ong, AC | 1 |
| Wilmer, MJ | 1 |
| van den Heuvel, L | 1 |
| Bultynck, G | 1 |
| Parys, JB | 1 |
| Missiaen, L | 1 |
| Levtchenko, E | 1 |
| De Smedt, H | 1 |
| McCarty, MF | 1 |
| Barroso-Aranda, J | 1 |
| Contreras, F | 1 |
| Takiar, V | 1 |
| Nishio, S | 1 |
| Seo-Mayer, P | 1 |
| King, JD | 1 |
| Li, H | 1 |
| Zhang, L | 1 |
| Karihaloo, A | 1 |
| Somlo, S | 1 |
| Caplan, MJ | 1 |
| Burtey, S | 1 |
| Steinman, TI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.[NCT02903511] | Phase 2 | 56 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine measurements at baseline and after 3, 6, 9 and 12 months. Change from baseline at 12 months is reported. (NCT02903511)
Timeframe: 12 months
| Intervention | mL/min/1.73 m^2 (Mean) |
|---|---|
| Metformin | -0.41 |
| Placebo | -3.35 |
Total kidney volume will be measured by MRI (magnetic resonance imaging) at baseline and at 12 months. Percentage change from baseline in height-adjusted total kidney volume is reported. (NCT02903511)
Timeframe: 12 months
| Intervention | percent change (Mean) |
|---|---|
| Metformin | 3.45 |
| Placebo | 3.15 |
Serious adverse events occurring from the time of signing informed consent until the end of the study will be monitored in both treatment arms (NCT02903511)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 2 |
| Placebo | 0 |
Percentage of participants who at the end of 12 months are still prescribed the full randomized dose of metformin or placebo, and the percentage of participants who are prescribed at least 50% of the randomized dose (NCT02903511)
Timeframe: 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Full Dose | 50% Dose | |
| Metformin | 50 | 82 |
| Placebo | 100 | 100 |
5 reviews available for metformin and ADPKD
| Article | Year |
|---|---|
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease.
Topics: Cysts; Disease Progression; Humans; Metformin; Polycystic Kidney, Autosomal Dominant; Somatostatin | 2022 |
Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.
Topics: Antioxidants; Chalcones; Curcumin; Diterpenes; Diterpenes, Kaurane; Emodin; Epoxy Compounds; Estroge | 2021 |
Autosomic dominant polycystic kidney disease and metformin: Old knowledge and new insights on retarding progression of chronic kidney disease.
Topics: Diabetes Mellitus, Type 2; Humans; Kidney; Metformin; Mutation; Polycystic Kidney, Autosomal Dominan | 2022 |
[Slow the pace of renal failure in autosomal dominant polycystic kidney disease: hopes and disappointments].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chromosomes, Human, Pair 16; Clini | 2011 |
Polycystic kidney disease: a 2011 update.
Topics: Antineoplastic Agents; Benzazepines; Curcumin; Everolimus; Gastrointestinal Agents; Glomerular Filtr | 2012 |
3 trials available for metformin and ADPKD
| Article | Year |
|---|---|
Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice.
Topics: Animals; Cysts; Disease Models, Animal; Female; Kidney; Lactic Acid; Male; Metformin; Mice; Mice, Tr | 2022 |
Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
Topics: Adult; Disease Progression; Feasibility Studies; Glomerular Filtration Rate; Humans; Kidney; Metform | 2022 |
A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Topics: Adolescent; Adult; Clinical Trials, Phase II as Topic; Cysts; Disease Progression; Dose-Response Rel | 2018 |
10 other studies available for metformin and ADPKD
| Article | Year |
|---|---|
PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.
Topics: Adenosine Monophosphate; AMP-Activated Protein Kinases; Animals; Cystic Fibrosis Transmembrane Condu | 2022 |
Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cyclic AMP; | 2019 |
TAMEing ADPKD with metformin: safe and effective?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Polycystic Kidney, Autosomal Domi | 2021 |
Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cell Proliferation; Cloaca; Cysts; Disease Models | 2017 |
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
Topics: Adult; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male; Met | 2018 |
The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease.
Topics: Animals; Deoxyglucose; Disease Models, Animal; Drug Therapy, Combination; Kidney; MAP Kinase Signali | 2019 |
ADPKD and metformin: from bench to bedside.
Topics: Adult; Diabetes Mellitus; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hypoglyce | 2019 |
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.
Topics: Animals; Drug Synergism; Gene Knockdown Techniques; Humans; Metformin; Mice; Mutation; Polycystic Ki | 2014 |
Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cystic Fibrosis Transmembrane Conductance Regulat | 2009 |
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Cell Proliferation; Cystic Fibrosis Transmembrane | 2011 |